Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02177812 |
| Title | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | CAN | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Augusta | Georgia | 30912 | United States | Details | |
| GSK Investigational Site | Bronx | New York | 10461 | United States | Details | |
| GSK Investigational Site | Bronx | New York | 10467 | United States | Details | |
| GSK Investigational Site | New York | New York | 10065 | United States | Details | |
| GSK Investigational Site | Houston | Texas | 77030 | United States | Details | |
| GSK Investigational Site | Melbourne | Victoria | 3004 | Australia | Details | |
| GSK Investigational Site | Toronto | Ontario | M5G 2M9 | Canada | Details | |
| GSK Investigational Site | Toronto | Ontario | M5G 2M | Canada | Details |